Skip to search formSkip to main contentSkip to account menu

AKB-9778

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Aniline CompoundsSulfonic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
VE-PTP phosphatase: a new target for diabetic kidney disease
2018
2018
Topical or Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in NZW Rabbits
2016
2016
The Tie2 Activator AKB-9778, Used In Combination With Ranibizumab, Enhances Reduction Of Diabetic Macular Edema Compared To Ranibizumab Monotherapy
2014
2014
A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of…
2010
2010
Abstract 1560: VE-PTP inhibitor AKB-9778 mitigates IL-2-induced VLS and interacts positively with IL-2 against melanoma and renal cancer tumors in mice
IL-2 induces complete responses (CR) durable more than 10 years in a subpopulation of patients with advanced melanoma or renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)